TRITEC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Tritec, and what generic alternatives are available?
Tritec is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in TRITEC is ranitidine bismuth citrate. There are forty-three drug master file entries for this compound. Additional details are available on the ranitidine bismuth citrate profile page.
Summary for TRITEC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 19 |
Patent Applications: | 101 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TRITEC at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for TRITEC
US Patents and Regulatory Information for TRITEC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRITEC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TRITEC
See the table below for patents covering TRITEC around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
New Zealand | 244390 | USE OF RANITIDINE BISMUTH SULPHATE AND ONE OR MORE HELICOBACTER PYLORI INHIBITING ANTIBIOTICS TO PREPARE PHARMACEUTICAL COMPOSITIONS | ⤷ Try a Trial |
Denmark | 351789 | ⤷ Try a Trial | |
Hungary | 206104 | PROCESS FOR PRODUCING FURAN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS ACTIVE INGREDIENT | ⤷ Try a Trial |
United Kingdom | 9019875 | ⤷ Try a Trial | |
Finland | 90538 | ⤷ Try a Trial | |
Slovakia | 287892 | PHARMACEUTICAL AGENTS FOR TREATING OF STOMACH AND INTESTINE DEFFECTS | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |